Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of subcutaneous ustekinumab or guselkumab in pediatric juvenile psoriatic arthritis
NL-OMON53596Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ustekinumab and guselkumab in juvenile psoriatic arthritis (JPsA) (2 cohorts), sponsored by Janssen Pharmaceutical. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
ustekinumabguselkumab
03
Conditions
juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on NL-OMON53596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53596.